Advances in PARP Inhibitors for Prostate Cancer
Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair. PARPi is a promising drug class that has gained significant traction in the last decade with good outcomes in different cancers. Several trials have sought...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/6/1849 |
| _version_ | 1797613000483405824 |
|---|---|
| author | Steven Tisseverasinghe Boris Bahoric Maurice Anidjar Stephan Probst Tamim Niazi |
| author_facet | Steven Tisseverasinghe Boris Bahoric Maurice Anidjar Stephan Probst Tamim Niazi |
| author_sort | Steven Tisseverasinghe |
| collection | DOAJ |
| description | Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair. PARPi is a promising drug class that has gained significant traction in the last decade with good outcomes in different cancers. Several trials have sought to test its effectiveness in metastatic castration resistant prostate cancer (mCRPC). We conducted a comprehensive literature review to evaluate the current role of PARPi in this setting. To this effect, we conducted queries in the PubMed, Embase and Cochrane databases. We reviewed and compared all major contemporary publications on the topic. In particular, recent phase II and III studies have also demonstrated the benefits of olaparib, rucaparib, niraparib, talazoparib in CRPC. Drug effectiveness has been assessed through radiological progression or overall response. Given the notion of synthetic lethality and potential synergy with other oncological therapies, several trials are looking to integrate PARPi in combined therapies. There remains ongoing controversy on the need for genetic screening prior to treatment initiation as well as the optimal patient population, which would benefit most from PARPi. PARPi is an important asset in the oncological arsenal for mCRPC. New combinations with PARPi may improve outcomes in earlier phases of prostate cancer. |
| first_indexed | 2024-03-11T06:48:45Z |
| format | Article |
| id | doaj.art-8d938e41356d48d68bab57df7f5fab23 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T06:48:45Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8d938e41356d48d68bab57df7f5fab232023-11-17T10:08:03ZengMDPI AGCancers2072-66942023-03-01156184910.3390/cancers15061849Advances in PARP Inhibitors for Prostate CancerSteven Tisseverasinghe0Boris Bahoric1Maurice Anidjar2Stephan Probst3Tamim Niazi4Department of Radiation Oncology, McGill University, Gatineau, QC J8V 3R2, CanadaDepartment of Radiation Oncology, McGill University, Montreal, QC H3A 0G4, CanadaDepartment of Urology, McGill University, Montreal, QC H3A 0G4, CanadaDepartment of Nuclear Medicine, McGill University, Montreal, QC H3A 0G4, CanadaDepartment of Radiation Oncology, McGill University, Montreal, QC H3A 0G4, CanadaPoly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair. PARPi is a promising drug class that has gained significant traction in the last decade with good outcomes in different cancers. Several trials have sought to test its effectiveness in metastatic castration resistant prostate cancer (mCRPC). We conducted a comprehensive literature review to evaluate the current role of PARPi in this setting. To this effect, we conducted queries in the PubMed, Embase and Cochrane databases. We reviewed and compared all major contemporary publications on the topic. In particular, recent phase II and III studies have also demonstrated the benefits of olaparib, rucaparib, niraparib, talazoparib in CRPC. Drug effectiveness has been assessed through radiological progression or overall response. Given the notion of synthetic lethality and potential synergy with other oncological therapies, several trials are looking to integrate PARPi in combined therapies. There remains ongoing controversy on the need for genetic screening prior to treatment initiation as well as the optimal patient population, which would benefit most from PARPi. PARPi is an important asset in the oncological arsenal for mCRPC. New combinations with PARPi may improve outcomes in earlier phases of prostate cancer.https://www.mdpi.com/2072-6694/15/6/1849prostate cancerPARP inhibitorstargeted therapy |
| spellingShingle | Steven Tisseverasinghe Boris Bahoric Maurice Anidjar Stephan Probst Tamim Niazi Advances in PARP Inhibitors for Prostate Cancer Cancers prostate cancer PARP inhibitors targeted therapy |
| title | Advances in PARP Inhibitors for Prostate Cancer |
| title_full | Advances in PARP Inhibitors for Prostate Cancer |
| title_fullStr | Advances in PARP Inhibitors for Prostate Cancer |
| title_full_unstemmed | Advances in PARP Inhibitors for Prostate Cancer |
| title_short | Advances in PARP Inhibitors for Prostate Cancer |
| title_sort | advances in parp inhibitors for prostate cancer |
| topic | prostate cancer PARP inhibitors targeted therapy |
| url | https://www.mdpi.com/2072-6694/15/6/1849 |
| work_keys_str_mv | AT steventisseverasinghe advancesinparpinhibitorsforprostatecancer AT borisbahoric advancesinparpinhibitorsforprostatecancer AT mauriceanidjar advancesinparpinhibitorsforprostatecancer AT stephanprobst advancesinparpinhibitorsforprostatecancer AT tamimniazi advancesinparpinhibitorsforprostatecancer |